Yükleniyor... / Loading...
Lifestyle Physical Activity and Cognitive Training Interventions
Bu çalışma, kalp-damar hastalığı olan yaşlı kadınlarda fiziksel aktivite ve bilişsel eğitim müdahalelerinin (Mind ve Move) etkilerini incelemiştir. Çalışmaya, 65 yaş ve üzeri, kalp-damar hastalığı öyküsü olan ve düzenli fiziksel aktivite yapmayan kadınlar katılmıştır. Bu, faz uygulanmayan bir çalışmadır ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * self-identified as women * ≥ 65 years old * read/speak English * patient in the Rush Heart Center for Women * history of CVD (e.g., coronary artery disease, hypertension) and receiving guideline-directed medical therapy when appropriate * no regular moderate-vigorous physical activity (≥ 30 minutes ≥ 3 days per week in the past month) * no cognitive training program in the past month * no disabilities preventing regular physical activity (Physical Activity Readiness Questionnaire, which includes cardiac and lung disease symptoms) * written approval from cardiology provider (Physical Activity Readiness Medical Examination); no self-reported significant hearing loss that interferes with normal conversation * access to a Bluetooth-capable phone or tablet Exclusion Criteria: * symptoms of unstable cardiac or pulmonary disease in the past month (Physical Activity Readiness Questionnaire) * blood pressure (systolic ≥ 160 or diastolic ≥ 100 mm Hg) * cognitive status score \< 19 on the blind version (for phone administration) of the Montreal Cognitive Assessment (MoCA) consistent with significant cognitive impairment * diagnosis of a neurological disease found in the electronic health record (e.g., Alzheimer's disease dementia, Parkinson's disease, vascular dementia) * transient ischemic attack or small-vessel stroke in the past three months * taking anti-psychotic medication * diabetes with an A1C ≥ 9.0 within the past six months * end-stage renal disease on dialysis (Stage 5)